MindMed to Present Data on the Preclinical Activity of MM-402 at the 36th Annual European College of Neuropsychopharmacology (ECNP) Congress
03 Ottobre 2023 - 1:30PM
Business Wire
– Preclinical data in ASD model demonstrate the
differences between MM-402 (R-MDMA), S-MDMA and Racemic MDMA with
enhanced pro-social effects and reduced hyperactivity –
Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED),
(the “Company” or “MindMed”), a clinical stage biopharmaceutical
company developing novel product candidates to treat brain health
disorders, announced today the upcoming presentation of preclinical
data of MM-402, the Company’s proprietary form of the R-enantiomer
of 3,4-Methylenedioxymethamphetamine (“MDMA”), in a model for
autism spectrum disorder (“ASD”) at the 36th Annual ECNP Congress
that is being held in Barcelona, Spain from October 7-10, 2023. The
Company plans to initiate its first clinical trial of MM-402 in Q4
2023.
The late-breaking poster entitled “MM-402 demonstrates better
efficacy than S(+)-3,4-MDMA or (±)-3,4-MDMA in Fmr1 knockout mice,
an animal model of autism spectrum disorder” will be presented on
Sunday, October 8, 2023 at 12:35 pm CET. This study demonstrated
that administration of MM-402 increased social interaction in a
characterized preclinical model of ASD. MM-402 exhibited a robust
effect on social interaction and was more potent than both S-MDMA
and racemic MDMA with reduced hyperactivity effects.
“We are pleased to share the research of our talented scientists
to build on our study of novel and promising therapies for brain
health disorders. We continue to demonstrate in preclinical models
the potential of our MM-402 product candidate to improve pro-social
effects while reducing the stimulant activity and other unwanted
effects,” said Robert Barrow, Chief Executive Officer and Director
of MindMed. “With this further preclinical evidence to support our
approach, we remain on track to initiate our Phase 1 clinical trial
of MM-402 later this year.”
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative product
candidates, with and without acute perceptual effects, targeting
neurotransmitter pathways that play key roles in brain health
disorders.
MindMed trades on NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the symbol MMED.
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute “forward-looking information” within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as “will”, “may”, “should”, “could”,
“intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”,
“potential” or “continue”, or the negative thereof or similar
variations. Forward-looking information in this news release
includes, but is not limited to, statements regarding anticipated
timing of initiation of the Company’s Phase 1 clinical trial of
MM-402 and the potential benefits of the product candidate. There
are numerous risks and uncertainties that could cause actual
results and the Company’s plans and objectives to differ materially
from those expressed in the forward-looking information, including
history of negative cash flows; limited operating history;
incurrence of future losses; availability of additional capital;
lack of product revenue; compliance with laws and regulations;
difficulty associated with research and development; risks
associated with clinical trials or studies; heightened regulatory
scrutiny; early stage product development; regulatory approval
processes; novelty of the psychedelic inspired medicines industry;
as well as those risk factors discussed or referred to herein and
the risks described in the Company’s Annual Report on Form 10-K for
the fiscal year ended December 31, 2022 and the Company’s Quarterly
Report on Form 10-Q for the fiscal quarter ended June 30, 2023
under headings such as “Special Note Regarding Forward-Looking
Statements,” and “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” and
other filings and furnishings made by the Company with the
securities regulatory authorities in all provinces and territories
of Canada which are available under the Company’s profile on SEDAR
at www.sedar.com and with the U.S. Securities and Exchange
Commission on EDGAR at www.sec.gov. Except as required by law, the
Company undertakes no duty or obligation to update any
forward-looking statements contained in this release as a result of
new information, future events, changes in expectations or
otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231003401155/en/
For Media & Investor Inquiries:
Maxim Jacobs, CFA Vice President, Investor Relations and
Corporate Communications Mind Medicine (MindMed) Inc. ir@mindmed.co
media@mindmed.co
Grafico Azioni Mind Medicine MindMed (NASDAQ:MNMD)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Mind Medicine MindMed (NASDAQ:MNMD)
Storico
Da Set 2023 a Set 2024